5 'Healthy' Dividends Paying Up to 14.1% | Investing.com Gold prices inch up, but on pace for weekly loss, as Iran war dents rate cut bets Oil edges up even as U.S. looks to lift crude supply - what's moving markets Forex insight: UBS warns of rising currency volatility amid Iran conflict Stocks end lower in choppy session after Netanyahu says Iran can't enrich uranium 5 'Healthy' Dividends Paying Up to 14.1% By Contrarian Outlook Author Brett Owens Stock Markets Published 03/20/2026, 05:16 AM 5 'Healthy' D ...

Viatris (NasdaqGS:VTRS) Update / briefing March 19, 2026 10:00 AM ET Company ParticipantsBill Szablewski - Head of Capital Markets and Investor RelationsCorinne Le Goff - Chief Commercial OfficerDoretta Mistras - CFOHemanth J. Varghese - Chief Strategy OfficerPhilippe Martin - Chief R&D OfficerScott Smith - CEOOperatorLadies and gentlemen, please welcome Head of Capital Markets, Viatris, Bill Szablewski.Bill SzablewskiGood morning, everyone, and welcome to our Viatris Investor Event. I'm Bill Szablewski, He ...

Pfizer FY Conference Summary Company Overview - **Company**: Pfizer (NYSE:PFE) - **Event**: FY Conference held on March 02, 2026 Key Points External Environment - Pfizer's CEO, Albert Bourla, expressed surprise at the competence of government negotiators during deal negotiations with the Trump administration, highlighting a pragmatic approach that led to successful outcomes for Pfizer [3][4] - The company addressed two major uncertainties: tariffs on patented products and potential drastic adjustments in U.S. drug pricing, both of which have been alleviated [4] Business Performance - Pfizer demonstrated strong execution in 2025, recovering from a significant revenue drop from $60 billion to $6 billion post-COVID, by reorganizing operations and revitalizing R&D without affecting top-line revenue [7] - The company announced four major priorities for the year, focusing on maximizing the value of recently acquired assets, delivering on R&D milestones, and maintaining dividends while investing in growth [8][9][10] Pipeline and R&D - Key acquisitions include Seagen, Becerra, and Biohaven, which account for 80% of an $80 billion investment in new businesses [8] - Pfizer is focusing on pivotal R&D milestones, including regulatory approvals and initiating 20 Phase III studies, with a significant emphasis on obesity treatments [9][11] - Oncology is highlighted as a critical area, with important compounds like SV from Seagen undergoing Phase III studies [11][12] Vaccine Development - Pfizer is advancing its pneumococcal vaccine and expects to maintain market leadership by 2030, with a focus on pediatric vaccinations [16][17][18] - The company is also working on vaccines for Lyme disease and C. difficile, aiming to address significant unmet medical needs [12][13] Obesity Market Strategy - Pfizer is optimistic about the obesity market, anticipating significant growth by 2030, despite current pricing pressures [19] - The company is developing a monthly product that could compete effectively in the obesity treatment space, differentiating itself from existing weekly products [20][21][23] - Pfizer has licensed a GLP-1 agonist in China, aiming to gain insights into commercialization strategies in a booming market [29] Regulatory Environment - Pfizer is navigating changes in FDA interactions, particularly regarding vaccine approvals, and is optimistic about recent reforms aimed at improving transparency in drug pricing [42][44] - The company sees potential benefits from PBM reforms that could enhance pricing transparency and reduce out-of-pocket costs for patients [45][46] Future Outlook - Two major trends shaping the industry include the rise of AI, which could transform research and manufacturing, and the emergence of China as a significant player in the pharmaceutical landscape [48][49] - Pfizer aims to enhance productivity and innovation to compete effectively against lower-cost, faster-moving competitors [49] Additional Insights - The company is committed to maintaining its dividend while investing in R&D and commercial infrastructure to maximize asset value [10] - Pfizer's approach to the obesity market includes a focus on consumer brand equity and direct sales strategies, drawing parallels to past successful product launches like Viagra [19][20][27]

Core Viewpoint - Viatris forecasts 2026 profit below analysts' expectations due to operational disruptions from a fire at its manufacturing facility in Nashik, India [1] Financial Performance - Viatris expects adjusted per-share profit for 2026 to be between $2.33 and $2.47, compared to analysts' average estimate of $2.49 [1] - The company anticipates annual revenue to be between $14.45 billion and $14.95 billion, while analysts estimate $14.35 billion [1] - Total revenue for the fourth quarter was $3.70 billion, reflecting a 5% increase year-over-year [1] - Revenue from the branded drugs unit, which constitutes the majority of total revenue, rose by 8% during the fourth quarter [1] - The company posted an adjusted profit of 57 cents per share for the quarter ended December 31, exceeding the estimate of 53 cents [1] Operational Challenges - A fire at the Nashik facility has led to a temporary shutdown, with operations expected to resume in April [1] - The manufacturing operations in India are already under strain due to a U.S. FDA restriction on imports from one of its facilities following federal requirement violations [1] Restructuring Plans - Viatris plans to cut up to 10% of its global workforce as part of a multi-year restructuring plan [1] - This restructuring is expected to generate savings of $600 million to $700 million once fully implemented, with total pre-tax charges estimated between $700 million and $850 million [1]

Pfizer plans to draw on lessons learned from rolling out Viagra as it maps out the launch of its first obesity medicine https://t.co/vLv7P4NyMC ...

1er avril 1998 pu être le plus gros poisson d'avril de tous les temps pour des milliers d'Américains. Mais il n'en fait rien. Ce 1er avril 1998, le médicament le plus célèbre et le plus contrefait du monde faisait son apparition dans toutes les pharmacies américaines.10 ans plus tard, le traitement du laboratoire Pfizer était commercialisé dans 120 pays pour générer un chiffre d'affaires de 2 milliards de dollars annuels. Les chercheurs de Pfizer s'étaient mis dans la tête d'utiliser une molécule, le cildén ...

Core Insights - Pfizer Inc. is exiting its HIV-focused joint venture, ViiV Healthcare, with a transaction valued at approximately $1.9 billion [2][3] - Shionogi will increase its stake in ViiV Healthcare from 10% to 21.7% by paying $2.13 billion for newly issued shares, while GSK retains a majority stake of 78.3% [3] - Pfizer will receive $1.88 billion for its 11.7% holding in ViiV Healthcare, and GSK will receive a $250 million special dividend as part of the deal [3] - The transaction is subject to regulatory approvals and is expected to close in the first quarter of 2026 [4] - Pfizer anticipates a challenging period ahead, with expectations of no revenue growth until 2029 due to declining sales of its COVID vaccine and treatment, price cuts, and loss of patent protection on key drugs [4] - Pfizer's CEO indicated preparations for a consumer-driven obesity drug market, which could rival the success of Viagra, despite not expecting rapid growth in the cash-pay obesity market [5][6]

Core Viewpoint - Pfizer is positioning itself to enter the consumer market for obesity drugs, aiming for a market impact similar to that of its erectile dysfunction drug Viagra, which was launched in 1998 [1] Group 1 - Pfizer's CEO, Albert Bourla, indicated the company's strategic focus on obesity drugs, highlighting the potential for significant market growth [1] - The company draws parallels between the anticipated success of obesity drugs and the historical performance of Viagra, suggesting a robust consumer demand [1]

Core Insights - Viatris is viewed as three distinct businesses: a global generics footprint, established products from the Upjohn acquisition, and a growing innovative segment [2] Group 1 - The global generics business includes products from Mylan and features iconic brands such as Lipitor, Norvasc, Xanax, Viagra, and Celebrex [2] - The company faced self-inflicted challenges earlier in the year, particularly with the Indore situation [3]

Summary of Viatris Conference Call Company Overview - **Company**: Viatris - **Business Segments**: - Global generics footprint (originating from Mylan) - Established products (notable brands include Lipitor, Norvasc, Xanax, Viagra, Celebrex from Upjohn acquisition) - Growing innovative segment [2][3] Core Points and Arguments - **Strategic Review**: Viatris is undergoing an enterprise-wide strategic review to assess its structure and cost efficiency, aiming for sustainable revenue and earnings growth beyond 2026 [4][20] - **Financial Performance**: - The company has returned over $1 billion to shareholders through dividends and share repurchases this year [3] - Anticipates approximately $500 million in new revenues annually from the base business, with a net growth of around $200 million after accounting for losses and price declines [8] - Internal expectations for revenue growth are higher than market estimates, with a goal to achieve continuous earnings growth over the next three to five years [7][26] - **Operating Leverage**: The company aims to improve operating leverage, targeting a growth profile shift from 1% to 3-5% [9][10] Pipeline and Product Development - **Innovative Assets**: Viatris is focusing on developing innovative products, including fast-acting meloxicam, which shows a faster onset of action compared to competitors [38][39] - **CNS Assets in Japan**: The acquisition of Aculys added CNS assets to Viatris' portfolio, with a strategic focus on growing revenues in the challenging Japanese market [32][34] - **Upcoming Launches**: The company is preparing for the launch of several products, including meloxicam and antiplatelet drugs, with significant market potential [46][63] Market Dynamics and Challenges - **External Challenges**: The company has faced external challenges such as tariffs, policy changes, and FDA regulations, which have impacted operations [2][3] - **Cost Structure Review**: Viatris is reviewing its cost structure post-merger and divestitures, aiming for significant cost savings while ensuring that these savings are sustainable [20][21] Investment and Capital Allocation - **Capital Deployment**: Viatris generates approximately $2 billion in free cash flow annually, with plans to allocate capital evenly between shareholder returns and business development [28][29] - **Focus on High-Margin Assets**: The company is looking to acquire high-margin, revenue-generating assets, particularly in the U.S. and Japan [35] Other Important Insights - **Market Positioning**: Viatris is positioning its innovative products as differentiated solutions in the market, with a focus on addressing unmet medical needs [39][63] - **Long-Term Vision**: The management emphasizes a long-term vision for growth, with a commitment to maintaining a strong base business while investing in innovation [6][26] This summary encapsulates the key points discussed during the Viatris conference call, highlighting the company's strategic direction, financial performance, product pipeline, and market challenges.